Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
Public ClinicalTrials.gov record NCT02065700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) (NCT01888874) or GLPG0634-CL-204 (DARWIN2) (NCT01894516), and were evaluated for any side effects that might have occured (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants were also examined for long-term effects of filgotinib administration on disease activity (efficacy), participant's disability, fatigue, and quality of life.
Study identification
- NCT ID
- NCT02065700
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 739 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 24, 2014
- Primary completion
- Jan 18, 2023
- Completion
- Jan 18, 2023
- Last update posted
- Jun 3, 2024
2014 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arthro, Arthritis Care & Research | Gilbert | Arizona | — | — |
| Arizona Arthritis & Rheumatology Research PLLC | Mesa | Arizona | — | — |
| C.V. Mehta MD Medical Corp. | Hemet | California | — | — |
| Desert Medical Advances | Palm Desert | California | — | — |
| RASF Clinical Research Center | Boca Raton | Florida | — | — |
| Millenium Research | Ormond Beach | Florida | — | — |
| Lovelace Scientific Resources | Venice | Florida | — | — |
| Springfield Clinic | Springfield | Illinois | — | — |
| Klein and Associates MD, PA | Hagerstown | Maryland | — | — |
| Physicians East | Greenville | North Carolina | — | — |
| Health Research of Oklahoma | Oklahoma City | Oklahoma | — | — |
| Low County Rheumatology PA | Charleston | South Carolina | — | — |
| West Tennessee Research Institute | Jackson | Tennessee | — | — |
| Austin Rheumatology Research PA | Austin | Texas | — | — |
| Pioneer Research Solutions Inc | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02065700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02065700 live on ClinicalTrials.gov.